Review of anti-vEGF therapy in proliferative diabetic retinopathy

Maria Stephanie R. Jardeleza, Joan W. Miller

Research output: Contribution to journalReview articlepeer-review

77 Scopus citations


Proliferative diabetic retinopathy (PDR) is a visually significant complication of diabetes mellitus. Pan-retinal photocoagulation (PRP) remains the standard treatment of choice. However, adverse effects of and clinical barriers to PRP have led to exploration of alternative and adjunctive therapeutic strategies in the treatment of proliferative disease. Inhibition of ocular vascular endothelial growth factor (VEGF) has emerged as a promising treatment modality for PDR. This review summarizes results from published studies using intravitreal anti-VEGF agents singly and in combination with standard therapeutic regimens in the treatment of proliferative diabetic retinopathy.

Original languageEnglish (US)
Pages (from-to)87-92
Number of pages6
JournalSeminars in Ophthalmology
Issue number2
StatePublished - Mar 2009
Externally publishedYes


  • Anti-VEGF treatment
  • Proliferative diabetic retinopathy
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Review of anti-vEGF therapy in proliferative diabetic retinopathy'. Together they form a unique fingerprint.

Cite this